These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9514801)

  • 1. Differential expression of trypsin in human ovarian carcinomas and low-malignant-potential tumors.
    Hirahara F; Miyagi E; Nagashima Y; Miyagi Y; Yasumitsu H; Koshikawa N; Nakatani Y; Nakazawa T; Udagawa K; Kitamura H; Minaguchi H; Miyazaki K
    Gynecol Oncol; 1998 Feb; 68(2):162-5. PubMed ID: 9514801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of long-term in vitro cultures of human ovarian cystadenomas and LMP tumors and examination of their spectrum of expression of matrix-degrading proteinases.
    Luo MP; Gomperts B; Imren S; DeClerck YA; Ito M; Velicescu M; Felix JC; Dubeau L
    Gynecol Oncol; 1997 Dec; 67(3):277-84. PubMed ID: 9441775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas.
    Datar RH; Naritoku WY; Li P; Tsao-Wei D; Groshen S; Taylor CR; Imam SA
    Gynecol Oncol; 1999 Sep; 74(3):338-45. PubMed ID: 10479490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
    Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A
    Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study.
    Sangoi AR; McKenney JK; Dadras SS; Longacre TA
    Am J Surg Pathol; 2008 Feb; 32(2):261-8. PubMed ID: 18223329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. u-PA expression in benign, borderline and malignant ovarian tumors.
    Kiziridou AD; Toliou T; Stefanou D; Agnantis N
    Anticancer Res; 2002; 22(2A):985-90. PubMed ID: 12014682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer.
    Brown TJ; Shaw PA; Karp X; Huynh MH; Begley H; Ringuette MJ
    Gynecol Oncol; 1999 Oct; 75(1):25-33. PubMed ID: 10502421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
    Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
    Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
    Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
    Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors.
    McCluskey LL; Chen C; Delgadillo E; Felix JC; Muderspach LI; Dubeau L
    Gynecol Oncol; 1999 Jan; 72(1):87-92. PubMed ID: 9889036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
    Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC
    Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer.
    Zheng W; Luo MP; Welt C; Lambert-Messerlian G; Sung CJ; Zhang Z; Ying SY; Schneyer AL; Lauchlan SC; Felix JC
    Gynecol Oncol; 1998 Apr; 69(1):23-31. PubMed ID: 9570994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
    Meinhold-Heerlein I; Bauerschlag D; Hilpert F; Dimitrov P; Sapinoso LM; Orlowska-Volk M; Bauknecht T; Park TW; Jonat W; Jacobsen A; Sehouli J; Luttges J; Krajewski M; Krajewski S; Reed JC; Arnold N; Hampton GM
    Oncogene; 2005 Feb; 24(6):1053-65. PubMed ID: 15558012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation margins of ovarian tumor pathology: first incidences of epithelial ovarian tumors monitored by marker antibodies.
    van Niekerk CC; Vooijs P; Casparie-van Velsen IJ; Poels LG
    Cancer Detect Prev; 1997; 21(3):247-57. PubMed ID: 9167042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucinous tumors of the ovary: a review.
    Hart WR
    Int J Gynecol Pathol; 2005 Jan; 24(1):4-25. PubMed ID: 15626914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of extracellular matrix proteins in ovarian serous tumors.
    Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
    Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.